(Q37763156)

22 August 2017

1 reference

title

Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise (English)

1 reference

22 August 2017

1 reference

1 reference

Ioannis Zachos

1

1 reference

22 August 2017

Panagiotis A Konstantinopoulos

2

1 reference

22 August 2017

Vassilios Tzortzis

3

1 reference

22 August 2017

Stavros Gravas

4

1 reference

22 August 2017

Anastasios Karatzas

5

1 reference

22 August 2017

Michalis V Karamouzis

6

1 reference

22 August 2017

Michael Melekos

7

1 reference

22 August 2017

Athanasios G Papavassiliou

8

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

875-887

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Therapy of invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Second-line therapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Systemic chemotherapy for advanced bladder cancer: update and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

The epidermal growth factor receptor and the prognosis of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Salvage of nonmaturing native fistulas by using angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Angiogenic factors and bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Molecular biology of bladder cancer: prognostic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Treatment of metastatic urothelial cancer: opportunities for drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

The regressing thin malignant melanoma: a distinctive lesion with metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

17-AAG: mechanisms of antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Recent advances of MEK inhibitors and their clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Polo-like kinases (Plks) and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Src and focal adhesion kinase as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.496450

10.1517/13543784.2010.496450

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference